M&A Deal Summary |
|
|---|---|
| Date | 2016-02-22 |
| Target | Bristol-Myers - HIV R&D portfolio |
| Sector | Life Science |
| Buyer(s) | ViiV Healthcare |
| Sellers(s) | Bristol-Myers Squibb |
| Deal Type | Divestiture |
| Deal Value | 350M USD |
SEARCH BY
Try For Free 7-Day Free Trial
ViiV Healthcare is a global specialist HIV company.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 1 of 1 |
| Country (United States) | 1 of 1 |
| Year (2016) | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 32,200 |
| Revenue | 46.2B USD (2022) |
Bristol-Myers Squibb is a life science company engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes. The majority of Bristol-Myers Squibb's revenue comes from products in the following therapeutic classes: cardiovascular; virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; immunoscience; and metabolics. Bristol-Myers Squibb was incorporated in 1887 and is based in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 13 |
| Sector (Life Science) | 2 of 5 |
| Type (Divestiture) | 6 of 9 |
| Country (United States) | 7 of 8 |
| Year (2016) | 1 of 1 |
| Size (of disclosed) | 6 of 6 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-11-02 |
Cardioxyl Pharmaceuticals
Chapel Hill, North Carolina, United States Cardioxyl Pharmaceuticals, Inc. is a developer of novel therapeutic agents for the treatment of cardiovascular disease. |
Buy | $300M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2016-03-23 |
Padlock Therapeutics
Cambridge, Massachusetts, United States Padlock Therapeutics, Inc. is a biotechnology company dedicated to creating new medicines to treat destructive autoimmune diseases. |
Buy | $225M |
